卡非佐米联合米托坦对人肾上腺皮质癌细胞H295R、SW13增殖及细胞周期的影响
发布时间：2018-08-14 17:54
【摘要】：目的探讨卡非佐米联合米托坦对人肾上腺皮质癌(ACC)细胞H295R、SW13增殖及细胞周期的影响。方法体外培养人ACC细胞H295R、SW13,采用MTT法确定米托坦作用H295R、SW13细胞48 h时的半数有效抑制浓度(IC_(50))值分别为18.42、62.37μmol/L,卡非佐米分别为3.86、11.62μmol/L。将两种对数生长期细胞随机分为对照组、卡非佐米组、米托坦组及序贯给药的卡非佐米→米托坦组、卡非佐米+米托坦组、米托坦→卡非佐米组,给药浓度分别为两种药物IC_(50)值的1/8、1/4、1/2、1、2倍,检测各浓度干预48 h时各组细胞增殖抑制率。根据Chou-Talaly公式计算IC_(50)及2倍IC_(50)作用下两种药物序贯给药时的联合指数(CI)。将两种对数生长期细胞随机分为对照组、米托坦单药组(25、50μmol/L)、卡非佐米单药组(1μmol/L)、卡非佐米(1μmol/L)→米托坦(25、50μmol/L)组,药物干预48 h时检测细胞增殖抑制率。将两种对数生长期细胞随机分为空白组、米托坦组、卡非佐米组、卡非佐米→米托坦组,后三组以IC_(50)药物浓度干预96 h,采用流式细胞仪检测细胞周期。结果 H295R及SW13细胞在IC_(50)及2倍IC_(50)浓度下,卡非佐米→米托坦组细胞增殖抑制率均高于米托坦→卡非佐米组及卡非佐米+米托坦组,米托坦→卡非佐米组均高于卡非佐米+米托坦组,组间比较P均0.05。H295R和SW13细胞在米托坦、卡非佐米IC_(50)及2倍IC_(50)浓度条件下,卡非佐米→米托坦组和米托坦+卡非佐米组中两药的CI值均1,且卡非佐米→米托坦组两药的CI值均小于米托坦+卡非佐米组(P均0.05);米托坦→卡非佐米组中两药的CI值均1,且均高于卡非佐米→米托坦组和米托坦+卡非佐米组(P均0.05)。1μmol/L卡非佐米与25、50μmol/L米托坦联合的卡非佐米→米托坦组H295R及SW13增殖抑制率分别高于25、50μmol/L米托坦组(P均0.05)。四组G1、G2/M、S期细胞百分比比较差异均无统计学意义(P均0.05)。结论卡非佐米联合米托坦对ACC细胞存在序贯依赖性的协同抑制细胞增殖作用,给予卡非佐米后给予米托坦的抗增殖作用最佳,但两药联合对细胞周期无明显影响。
[Abstract]:Objective to investigate the effects of Carfezomi combined with Mitotam on the proliferation and cell cycle of human adrenocortical carcinoma (ACC) cell line H295 RN SW13. Methods Human ACC cells were cultured in vitro. MTT assay was used to determine the median effective inhibitory concentrations (IC50) of H295RNSW13 cells at 48 h after treatment with Mitotam (18.42 渭 mol / L) and carbofezomil (3.8611.62 渭 mol / L), respectively. Two kinds of logarithmic growth cells were randomly divided into control group, Carfezomi group, mitosartan group and sequential administration of Carfezomidone group, Carfezomitartan group, mitosomide group, and mitosomide group. The concentration of IC50 was 1 / 8 / 1 / 4 / 2 / 1 / 2 of IC50, respectively. The cell proliferation inhibition rate of each group was measured at 48 h after each concentration was interfered. Calculation of the combined index (CI). For sequential administration of two drugs under the action of IC _ (50) and 2 times IC _ (50) according to Chou-Talaly formula Two kinds of logarithmic growth cells were randomly divided into control group, mitotam group (2550 渭 mol/L), captopamil monotherapy group (1 渭 mol/L) and carfezomi group (1 渭 mol/L). The inhibitory rate of cell proliferation was measured at 48 h after drug intervention. Two kinds of logarithmic growth cells were randomly divided into three groups: the control group, the Mitotam group and the carbazolitine group. The latter three groups were treated with IC50 for 96 h, and the cell cycle was measured by flow cytometry. Results at the concentration of IC50 and 2 times IC50, the cell proliferation inhibition rate in the group of Cafizolmitam and SW13 was higher than that in the group of mitotam and the group of caprizomitosamitone, and the inhibition rate of cell proliferation in the two groups was higher than that in the group of mitotazolidone and the group of mifetotazolam. The P average of 0.05.H295R and SW13 cells in the mitotam group was higher than that in the captozotocin group at the concentration of mitotam, captopamil IC _ (50) and 2 times IC50, and the difference between the two groups was observed. The CI values of the two drugs in the two groups were 1 and 1, respectively, and the CI values of the two drugs were lower than those of the mitotancaptopamil group (P 0.05), and the CI values of the two drugs were lower than those of the mitotam captopamil group (P 0.05), and the CI values of the two drugs were lower than those of the mitotancaptopamil group (P 0.05). The CI values were 1, and were higher than those in the two groups (P < 0. 05). The inhibition rates of H295R and SW13 proliferation in the mitotazolam group were higher than those in the two groups (P < 0. 05). The inhibitory rates of H295R and SW13 in the mitotazolam group were significantly higher than those in the 2 550 渭 mol/L mittopam group (P < 0. 05). There was no significant difference in the percentage of G _ 1 G _ 2 / M _ 2 / M _ 2 phase cells among the four groups (P 0.05). Conclusion Carfezomi combined with mitotam has a sequential synergistic inhibitory effect on the proliferation of ACC cells. The antiproliferative effect of the combination of the two drugs is the best, but the combination of the two drugs has no obvious effect on the cell cycle.
【作者单位】： 广西医科大学第一附属医院;
【基金】：国家自然科学基金资助项目(81060220)
【分类号】：R736.6
本文编号：2183648
[Abstract]:Objective to investigate the effects of Carfezomi combined with Mitotam on the proliferation and cell cycle of human adrenocortical carcinoma (ACC) cell line H295 RN SW13. Methods Human ACC cells were cultured in vitro. MTT assay was used to determine the median effective inhibitory concentrations (IC50) of H295RNSW13 cells at 48 h after treatment with Mitotam (18.42 渭 mol / L) and carbofezomil (3.8611.62 渭 mol / L), respectively. Two kinds of logarithmic growth cells were randomly divided into control group, Carfezomi group, mitosartan group and sequential administration of Carfezomidone group, Carfezomitartan group, mitosomide group, and mitosomide group. The concentration of IC50 was 1 / 8 / 1 / 4 / 2 / 1 / 2 of IC50, respectively. The cell proliferation inhibition rate of each group was measured at 48 h after each concentration was interfered. Calculation of the combined index (CI). For sequential administration of two drugs under the action of IC _ (50) and 2 times IC _ (50) according to Chou-Talaly formula Two kinds of logarithmic growth cells were randomly divided into control group, mitotam group (2550 渭 mol/L), captopamil monotherapy group (1 渭 mol/L) and carfezomi group (1 渭 mol/L). The inhibitory rate of cell proliferation was measured at 48 h after drug intervention. Two kinds of logarithmic growth cells were randomly divided into three groups: the control group, the Mitotam group and the carbazolitine group. The latter three groups were treated with IC50 for 96 h, and the cell cycle was measured by flow cytometry. Results at the concentration of IC50 and 2 times IC50, the cell proliferation inhibition rate in the group of Cafizolmitam and SW13 was higher than that in the group of mitotam and the group of caprizomitosamitone, and the inhibition rate of cell proliferation in the two groups was higher than that in the group of mitotazolidone and the group of mifetotazolam. The P average of 0.05.H295R and SW13 cells in the mitotam group was higher than that in the captozotocin group at the concentration of mitotam, captopamil IC _ (50) and 2 times IC50, and the difference between the two groups was observed. The CI values of the two drugs in the two groups were 1 and 1, respectively, and the CI values of the two drugs were lower than those of the mitotancaptopamil group (P 0.05), and the CI values of the two drugs were lower than those of the mitotam captopamil group (P 0.05), and the CI values of the two drugs were lower than those of the mitotancaptopamil group (P 0.05). The CI values were 1, and were higher than those in the two groups (P < 0. 05). The inhibition rates of H295R and SW13 proliferation in the mitotazolam group were higher than those in the two groups (P < 0. 05). The inhibitory rates of H295R and SW13 in the mitotazolam group were significantly higher than those in the 2 550 渭 mol/L mittopam group (P < 0. 05). There was no significant difference in the percentage of G _ 1 G _ 2 / M _ 2 / M _ 2 phase cells among the four groups (P 0.05). Conclusion Carfezomi combined with mitotam has a sequential synergistic inhibitory effect on the proliferation of ACC cells. The antiproliferative effect of the combination of the two drugs is the best, but the combination of the two drugs has no obvious effect on the cell cycle.
【作者单位】： 广西医科大学第一附属医院;
【基金】：国家自然科学基金资助项目(81060220)
【分类号】：R736.6
【相似文献】
相关期刊论文 前1条
1 李一春;张海涛;秦勇;;米托坦逆转P-gp介导的人卵巢癌细胞的耐药作用及机制探讨[J];山东医药;2013年42期
，本文编号：2183648
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2183648.html
